BRCA2 pathogenic variants

About

Gene context: BRCA2

Biomarker Type: Germline Variant

Present: True

Chromosome: 13

Requires Pathogenic: True


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib HC
Sensitivity (+) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib HC
Sensitivity (+) BRCA2 pathogenic variants Ovarian Epithelial Tumor Olaparib HC
Sensitivity (+) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Olaparib HC
Sensitivity (+) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Olaparib HC
Sensitivity (+) BRCA2 pathogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib HC
Sensitivity (+) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib HC
Sensitivity (+) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib HC
Sensitivity (+) BRCA2 pathogenic variants Pancreatic Adenocarcinoma Olaparib HC
Sensitivity (+) BRCA2 pathogenic variants Prostate Adenocarcinoma Olaparib HC
Sensitivity (+) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone HC
Sensitivity (+) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone HC
Sensitivity (+) BRCA2 pathogenic variants Ovarian Epithelial Tumor Rucaparib FDA
Sensitivity (+) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Rucaparib FDA
Sensitivity (+) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Rucaparib FDA
Sensitivity (+) BRCA2 pathogenic variants Prostate Adenocarcinoma Rucaparib FDA
Sensitivity (+) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Talazoparib FDA
Sensitivity (+) BRCA2 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib FDA
Sensitivity (+) BRCA2 pathogenic variants Ovarian Epithelial Tumor Niraparib FDA
Sensitivity (+) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Niraparib FDA
Sensitivity (+) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Niraparib FDA
Sensitivity (+) BRCA2 pathogenic variants Ovarian Epithelial Tumor Olaparib FDA
Sensitivity (+) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Olaparib FDA
Sensitivity (+) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Olaparib FDA
Sensitivity (+) BRCA2 pathogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib FDA
Sensitivity (+) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib FDA
Sensitivity (+) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib FDA
Sensitivity (+) BRCA2 pathogenic variants Ovarian Epithelial Tumor Olaparib FDA
Sensitivity (+) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Olaparib FDA
Sensitivity (+) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Olaparib FDA
Sensitivity (+) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib FDA
Sensitivity (+) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib FDA
Sensitivity (+) BRCA2 pathogenic variants Pancreatic Adenocarcinoma Olaparib FDA
Sensitivity (+) BRCA2 pathogenic variants Prostate Adenocarcinoma Olaparib FDA
Sensitivity (+) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone FDA
Sensitivity (+) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone FDA
Sensitivity (+) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone FDA